On 16 April 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCPChFeLV, lyophilisate and solvent for suspension for injection, intended for use in cats. The applicant for this veterinary medicinal product is Intervet International B.V.
Nobivac NXT HCPChFeLV is an immunological veterinary medicinal product (vaccine) containing feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live), feline panleucopenia virus, strain MW-1 (live), Chlamydia felis, strain Baker (live) and feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA in viral vector, replication deficient as the active substances.
The benefits of Nobivac NXT HCPChFeLV are its efficacy for the active immunisation of cats:
The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination for FHV, FCV and FeLV; 3 years for FPL and 1 year for Chlamydia felis.
Nobivac NXT HCPChFeLV is generally well tolerated at the recommended dose, The most common side effects are injection site swelling and elevated temperature (common).
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCPChFeLV and therefore recommends the granting of the marketing authorisation.
Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.